GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Genflow Biosciences GENF.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

1.74p

+0.58%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in GBP, from our data supplier.

FY2025

Revenue

—

FY2020FY2025

Net income

−£1.4m

FY2020FY2025

Free cash flow

−£1.4m

FY2020FY2025

Shareholders' equity

−£550,785

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Revenue——£169,854———
Gross profit−£1,093−£1,204−£1,034−£130——
Research and development£1.1m£1.2m£960,314£724,465£939—
Operating income−£2.0m−£1.6m−£2.0m−£1.8m−£6,499−£142,100
Net income−£1.4m−£1.6m−£1.6m−£1.3m−£6,510−£141,600
Diluted earnings per share-0.00-0.00-0.01-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assets£452,386£385,908£1.1m£2.6m£2,838£179,800
Cash and short-term investments£111,792£278,682£683,974£2.4m£2,542£176,500
Total liabilities£1.0m£788,916£345,738£250,988£648£31,000
Debt—————£4,500
Shareholders' equity−£550,785−£403,008£725,915£2.4m£2,190£148,800
Shares outstanding469m351m293m293m245m293m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−£1.4m−£1.1m−£1.7m−£1.4m−£4,395−£24,200
Capital spending−£5—−£2,439−£2,480——
Free cash flow−£1.4m−£1.1m−£1.7m−£1.4m−£4,395−£24,200

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——£292,804£292,804£122,554£122,554−£396,055£160,236
Gross profit——£292,804£292,804£122,554£122,554−£396,055£160,236
Operating income−£286,879−£286,879−£339,973−£339,973−£368,809−£368,809−£371,252−£531,488
Net income−£210,117−£210,117−£339,973−£339,973−£368,809−£368,809−£531,488−£531,488
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets£748,991£748,991£452,386£452,386£468,381£468,381£385,908£385,908
Cash and short-term investments£632,553£632,553£111,792£111,792£279,445£279,445£278,682£278,682
Shareholders' equity£189,853£189,853−£550,785−£550,785−£303,003−£303,003−£403,008−£403,008

Growth per year

Compound annual rate

3 years5 years10 years
Operating income3.2%69.8%—
Net income2.0%58.5%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-6.1-3.8-2.6-5.3
Price to sales——24.5—

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.